Châtillon, France, January 16, 2026DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of ...

DBV Technologies previously announced that it had raised €166.7 million in gross proceeds from the full exercise of warrants issued in its March 2025 financing, resulting in the creation of tens of ...

AMF Regulated InformationChâtillon, France, January 7, 2026Half-Year Report on the DBV Technologies Liquidity Contract with ...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years DBV Technologies (Euronext: DBV – ISIN: ...

The average one-year price target for DBV Technologies S.A. - Depositary Receipt (NasdaqCM:DBVT) has been revised to $21.61 / share. This is a decrease of 13.27% from the prior estimate of $24.92 ...

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive twenty-four month results from its Open-Label ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

Two of the leaders responsible for regulatory and product development at DBV Technologies are set to leave the company this month. The departures deprive DBV of senior members of its regulatory team ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...